CA3062763A1 - Diagnostic biomarkers for detecting, subtyping, and/or assessing progression of multiple sclerosis - Google Patents

Diagnostic biomarkers for detecting, subtyping, and/or assessing progression of multiple sclerosis Download PDF

Info

Publication number
CA3062763A1
CA3062763A1 CA3062763A CA3062763A CA3062763A1 CA 3062763 A1 CA3062763 A1 CA 3062763A1 CA 3062763 A CA3062763 A CA 3062763A CA 3062763 A CA3062763 A CA 3062763A CA 3062763 A1 CA3062763 A1 CA 3062763A1
Authority
CA
Canada
Prior art keywords
group
autoantigen
autoantibody
subject
specific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3062763A
Other languages
English (en)
French (fr)
Inventor
Robert G. Nagele
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rowan University
Original Assignee
Rowan University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rowan University filed Critical Rowan University
Publication of CA3062763A1 publication Critical patent/CA3062763A1/en
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/551—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being inorganic
    • G01N33/552—Glass or silica
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
CA3062763A 2017-05-10 2018-05-10 Diagnostic biomarkers for detecting, subtyping, and/or assessing progression of multiple sclerosis Pending CA3062763A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762504130P 2017-05-10 2017-05-10
US62/504,130 2017-05-10
PCT/US2018/032130 WO2018209126A1 (en) 2017-05-10 2018-05-10 Diagnostic biomarkers for detecting, subtyping, and/or assessing progression of multiple sclerosis

Publications (1)

Publication Number Publication Date
CA3062763A1 true CA3062763A1 (en) 2018-11-15

Family

ID=64104996

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3062763A Pending CA3062763A1 (en) 2017-05-10 2018-05-10 Diagnostic biomarkers for detecting, subtyping, and/or assessing progression of multiple sclerosis

Country Status (5)

Country Link
US (3) US20210003570A1 (https=)
EP (1) EP3622291A4 (https=)
JP (1) JP7146286B2 (https=)
CA (1) CA3062763A1 (https=)
WO (1) WO2018209126A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116113701A (zh) * 2020-08-03 2023-05-12 普利维尔治疗公司 编码parkin的aav载体及其用途

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110186962B (zh) * 2019-05-10 2021-06-25 天津大学 一种用于电容层析成像的不完整测量数据成像方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US5856092A (en) 1989-02-13 1999-01-05 Geneco Pty Ltd Detection of a nucleic acid sequence or a change therein
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5547839A (en) 1989-06-07 1996-08-20 Affymax Technologies N.V. Sequencing of surface immobilized polymers utilizing microflourescence detection
US5424186A (en) 1989-06-07 1995-06-13 Affymax Technologies N.V. Very large scale immobilized polymer synthesis
US5770358A (en) 1991-09-18 1998-06-23 Affymax Technologies N.V. Tagged synthetic oligomer libraries
US5384261A (en) 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
CA2124087C (en) 1991-11-22 2002-10-01 James L. Winkler Combinatorial strategies for polymer synthesis
US5861242A (en) 1993-06-25 1999-01-19 Affymetrix, Inc. Array of nucleic acid probes on biological chips for diagnosis of HIV and methods of using the same
US6027880A (en) 1995-08-02 2000-02-22 Affymetrix, Inc. Arrays of nucleic acid probes and methods of using the same for detecting cystic fibrosis
US5837832A (en) 1993-06-25 1998-11-17 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
US6090555A (en) 1997-12-11 2000-07-18 Affymetrix, Inc. Scanned image alignment systems and methods
US5578832A (en) 1994-09-02 1996-11-26 Affymetrix, Inc. Method and apparatus for imaging a sample on a device
US5631734A (en) 1994-02-10 1997-05-20 Affymetrix, Inc. Method and apparatus for detection of fluorescently labeled materials
US5856174A (en) 1995-06-29 1999-01-05 Affymetrix, Inc. Integrated nucleic acid diagnostic device
EP0902885A4 (en) 1996-05-16 2006-09-27 Affymetrix Inc SYSTEMS AND METHODS FOR DETECTION OF BRANDED PRODUCTS
ATE296898T1 (de) 1997-03-20 2005-06-15 Affymetrix Inc Iterative resequenzierung
US6201639B1 (en) 1998-03-20 2001-03-13 James W. Overbeck Wide field of view and high speed scanning microscopy
US6185030B1 (en) 1998-03-20 2001-02-06 James W. Overbeck Wide field of view and high speed scanning microscopy
US5936324A (en) 1998-03-30 1999-08-10 Genetic Microsystems Inc. Moving magnet scanner
US6218803B1 (en) 1999-06-04 2001-04-17 Genetic Microsystems, Inc. Position sensing with variable capacitance transducers
JP2004003989A (ja) 2002-03-15 2004-01-08 Affymetrix Inc 生物学的物質の走査のためのシステム、方法、および製品
US20050032074A1 (en) 2002-09-09 2005-02-10 Affymetrix, Inc. Custom design method for resequencing arrays
US7300788B2 (en) 2002-10-08 2007-11-27 Affymetrix, Inc. Method for genotyping polymorphisms in humans
CA2505515C (en) 2002-11-07 2013-08-27 Erasmus Universiteit Rotterdam Fret probes and methods for detecting interacting molecules
US7317415B2 (en) 2003-08-08 2008-01-08 Affymetrix, Inc. System, method, and product for scanning of biological materials employing dual analog integrators
JP2013528799A (ja) * 2010-05-13 2013-07-11 ユニバーシティ オブ メディスン アンド デンティストリー オブ ニュー ジャージー 神経変性疾患の検知および診断のための診断用自己抗体プロファイル
WO2013010003A1 (en) 2011-07-12 2013-01-17 University Of Medicine And Dentistry Of New Jersey Diagnostic biomarker profiles for the detection and diagnosis of alzheimer's disease
US9746482B2 (en) 2011-08-11 2017-08-29 Rowan University Diagnostic biomarker profiles for the detection and diagnosis of parkinsons disease
US11446398B2 (en) * 2016-04-11 2022-09-20 Obsidian Therapeutics, Inc. Regulated biocircuit systems

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116113701A (zh) * 2020-08-03 2023-05-12 普利维尔治疗公司 编码parkin的aav载体及其用途

Also Published As

Publication number Publication date
WO2018209126A1 (en) 2018-11-15
US20220390447A1 (en) 2022-12-08
US12174187B2 (en) 2024-12-24
US20220390448A1 (en) 2022-12-08
EP3622291A1 (en) 2020-03-18
JP2020519895A (ja) 2020-07-02
US20210003570A1 (en) 2021-01-07
JP7146286B2 (ja) 2022-10-04
EP3622291A4 (en) 2021-04-21

Similar Documents

Publication Publication Date Title
US20230393133A1 (en) Blood biomarker that predicts persistent cognitive dysfunction after concussion
EP2965090B1 (en) Methods and compositions for the diagnosis of alzheimer's disease
US20120178637A1 (en) Biomarkers and methods for detecting alzheimer's disease
US9746482B2 (en) Diagnostic biomarker profiles for the detection and diagnosis of parkinsons disease
US11187708B2 (en) Early stage Parkinson's disease diagnostic kits and methods
KR20160055780A (ko) 인지기능장애질환의 바이오 마커 및 당해 바이오 마커를 사용하는 인지기능장애질환의 검출방법
US12174187B2 (en) Methods for detecting multiple sclerosis (MS) diagnostic autoantibodies
CN113075414A (zh) 用于诊断眼表炎症和干眼病的方法和装置
US20150293120A1 (en) Marker sequences for rheumatoid arthritis
JP5924502B2 (ja) リンパ球性漏斗下垂体後葉炎のバイオマーカー及びその用途
US20100261881A1 (en) Marker sequences for rheumatoid arthritis and use thereof
US11619632B2 (en) Early-stage Alzheimer's disease autoantibody biomarkers, target antigens and diagnostic uses thereof
AU2021203920A1 (en) Biomarkers for detection of breast cancer
WO2017168014A1 (de) Markersequenzen für rheumatoide arthritis
EP2735875A1 (en) Marker sequences for Neuromyelitis Optica (NMO) and use thereof
US20250306021A1 (en) Sero-Reactive Antigens for Coccidioidomycosis
AU2008295291A1 (en) Marker sequences for multiple sclerosis and use thereof
HK40045405A (en) Methods and devices for diagnosing ocular surface inflammation and dry eye disease
HK1144015A (en) Marker sequences for rheumatoid arthritis and use thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220914

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20240815

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20241113

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250203

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250502

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250502